Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene

NEW YORK, May 28, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Quest Diagnostics Inc. (NYSE: DGX), Sarepta Therapeutics, Inc. (NASDAQ: SRPT), Incyte Corporation (NASDAQ: INCY) and Centene Corp. (NYSE: CNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3012-100free.

--
Gilead Sciences Inc. Analyst Notes
On May 20, 2014, Gilead Sciences Inc. (Gilead) released the results from its Phase 2a challenge study in healthy adult patients intranasally infected with respiratory syncytial virus (RSV). The Company announced that the study of GS-5806 has achieved its primary and secondary endpoints of lower viral load, improvements in total mucus weight, and symptom diary score compared to placebo. According to the Company, GS-5806 is an oral small molecule antiviral fusion inhibitor being evaluated for the treatment of respiratory syncytial virus (RSV). According to the Company, currently there is no effective antiviral treatment for RSV infection, which is a pathogen that infects the human respiratory tract, potentially leading to bronchiolitis and pneumonia. The full analyst notes on Gilead are available to download free of charge at:

http://www.analystsreview.com/GILD.pdf/Register

--
Quest Diagnostics Inc. Analyst Notes
On May 21, 2014, Quest Diagnostics Inc. (Quest Diagnostics) declared a quarterly cash dividend in the amount of $0.33 per share, payable on July 23, 2014 to shareholders of record of Quest Diagnostics common stock on July 9, 2014. The full analyst notes on Quest Diagnostics are available to download free of charge at:

http://www.analystsreview.com/DGX.pdf/Register

--
Sarepta Therapeutics, Inc. Analyst Notes
On May 22, 2014, Sarepta Therapeutics, Inc. (Sarepta Therapeutics) announced that it has entered into an agreement to acquire a multifunctional manufacturing facility spread across 26 acres of land in Massachusetts, which it intends to use for manufacturing investigational exon skipping therapies for Duchenne muscular dystrophy (DMD).The agreement comprises approximately $25 million in acquisition costs and planned enhancements, and is expected to be completed in July 2014. Commenting on the transaction, Chris Garabedian, President and CEO, said, "This strategic acquisition complements our existing internal manufacturing capability and global network of suppliers." The full analyst notes on Sarepta Therapeutics are available to download free of charge at:

http://www.analystsreview.com/SRPT.pdf/Register

--
Incyte Corporation Analyst Notes
On May 20, 2014, Incyte Corporation (Incyte) announced the list of investor conferences scheduled to be held in the month of June 2014, in which the Company intends to present. According to the schedule provided by the Company, it will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 10:30 a.m. EDT in New York; Goldman Sachs 35th Annual Global Healthcare Conference on Tuesday, June 10, 2014 at 10:40 a.m. PDT/1:40 p.m. EDT in Rancho Palos Verdes; and Wells Fargo Securities Research, Economics & Strategy 2014 Healthcare Conference on Wednesday, June 18, 2014 at 11:15 a.m. EDT in Boston. Live webcasts, as well as the replays of the aforementioned presentations, will be accessible via the Company's website under Investor Relations, Events and Webcasts. The full analyst notes on Incyte are available to download free of charge at:

http://www.analystsreview.com/INCY.pdf/Register

--
Centene Corp. Analyst Notes
On May 13, 2014, Centene Corp. (Centene) announced that the Company's subsidiary, IlliniCare Health (IlliniCare), has been awarded a five-year services agreement with Cook County Health & Hospital Systems. Under the agreement, IlliniCare will provide third party administrative services, care coordination, behavioral health, optometry and pharmacy benefits management services. The transaction is expected to commence on July 1, 2014. Jeff Joy, IlliniCare Health President and CEO, said, "Through this collaborative partnership, our combined organizations provide synergies of infrastructure and an optimal care delivery system. We believe our suite of administrative and cost containment solutions, coupled with a genuine passion for advancing the well-being of all community members, are a winning combination." The full analyst notes on Centene are available to download free of charge at:

http://www.analystsreview.com/CNC.pdf/Register

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED